| abstract |
The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of poorly directed cell signal transduction processes, in particular to influence the function of tyrosine and serine / threonine kinases and for the treatment of malignant or benign tumors and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver. |